NUI Maynooth spinout Avectas has added $20m to its coffers to develop cancer treatments.
Avectas, an Ireland-based cell engineering platform developer spun out of National University of Ireland (NUI) Maynooth, has received $20m in a funding round led by private investor Séamus Mulligan, according to the Irish Times.
Founded in 2012 as Profector Life Sciences, Avectas has built a cell engineering platform called Solupore that enables drug developers to create therapeutic cells by injecting advanced molecules including proteins or messenger RNA into cellular subtypes such as immune system T-cells.
The company raised…